A natural plant compound reduced pain by boosting endocannabinoids without binding to cannabinoid receptors
The triterpene beta-amyrin inhibited 2-AG breakdown without directly binding to cannabinoid receptors, suggesting a new class of indirect cannabinoid-based pain relief.
Quick Facts
What This Study Found
Previous research claimed the natural triterpenes alpha- and beta-amyrin bound directly to CB1 receptors at subnanomolar concentrations and relieved pain through cannabinoid receptors. This study challenged that finding.
Using validated binding assays, the researchers found no binding of either amyrin to human CB1 or CB2 receptors (Ki values greater than 10 micromolar, compared to the previously claimed 133 picomolar). Instead, beta-amyrin potently inhibited the breakdown of 2-AG (an endocannabinoid) without affecting anandamide breakdown.
Beta-amyrin only weakly inhibited purified MAGL but more potently inhibited 2-AG breakdown in cell and brain homogenates, suggesting it targeted multiple alpha,beta-hydrolases involved in 2-AG metabolism.
Key Numbers
No CB receptor binding (Ki > 10 micromolar vs previously claimed 133 pM). Beta-amyrin potently inhibited 2-AG hydrolysis. Weak inhibition of purified MAGL but potent inhibition in tissue homogenates.
How They Did This
In vitro pharmacology study using validated CB receptor binding assays (hCB1 and hCB2 transfected CHO-K1 cells), endocannabinoid transport assays, and enzyme activity measurements with both purified enzymes and cell/tissue homogenates.
Why This Research Matters
This study corrected the scientific record while uncovering a potentially more interesting mechanism: a natural compound that relieves pain by indirectly boosting endocannabinoids rather than directly activating cannabinoid receptors. This could avoid psychoactive side effects.
The Bigger Picture
Triterpenes are widely distributed in plants and already consumed in human diets. If they can boost endocannabinoid tone indirectly, they represent a new scaffold for developing non-psychoactive pain medications that work through the cannabinoid system.
What This Study Doesn't Tell Us
In vitro study only. The discrepancy with previous binding data was unexplained. The mechanism of 2-AG protection in tissue homogenates (beyond MAGL) was not fully characterized. No in vivo validation was included.
Questions This Raises
- ?Which specific hydrolases does beta-amyrin target beyond MAGL?
- ?Can triterpene-based drugs be developed for clinical pain management?
- ?Why did previous studies report direct CB1 binding?
Trust & Context
- Key Stat:
- No CB receptor binding, contradicting prior claims of sub-nanomolar affinity
- Evidence Grade:
- In vitro pharmacology study that corrected previous findings and identified a new mechanism. Well-controlled but lacks in vivo validation.
- Study Age:
- Published in 2012. Triterpene research for pain management has continued as a niche area of investigation.
- Original Title:
- The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.
- Published In:
- British journal of pharmacology, 167(8), 1596-608 (2012)
- Authors:
- Chicca, A, Marazzi, J, Gertsch, J
- Database ID:
- RTHC-00549
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could this plant compound replace cannabis for pain?
Beta-amyrin works differently from cannabis: rather than directly activating cannabinoid receptors, it boosts the body's own endocannabinoids by preventing their breakdown. This could provide pain relief without the high, but this study was only in test tubes, not in people.
Why does it matter that previous binding claims were wrong?
Accurate understanding of how a compound works is essential for drug development. If beta-amyrin works by boosting endocannabinoids rather than directly activating receptors, the drug development strategy would be completely different.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-00549APA
Chicca, A; Marazzi, J; Gertsch, J. (2012). The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.. British journal of pharmacology, 167(8), 1596-608. https://doi.org/10.1111/j.1476-5381.2012.02059.x
MLA
Chicca, A, et al. "The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.." British journal of pharmacology, 2012. https://doi.org/10.1111/j.1476-5381.2012.02059.x
RethinkTHC
RethinkTHC Research Database. "The antinociceptive triterpene β-amyrin inhibits 2-arachidon..." RTHC-00549. Retrieved from https://rethinkthc.com/research/chicca-2012-the-antinociceptive-triterpene-amyrin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.